Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aga Khan University | OTHER |
| Wellcome Trust | OTHER |
| University of Western Ontario, Canada | OTHER |
| GlaxoSmithKline |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Karachi, Pakistan. The cost-effectiveness of Vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.
Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence; is given as a single dose; lacks patent protection and requires less strict cold chain requirements. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (hepatitis A) was designed to determine the effectiveness and the feasibility of providing Vi vaccine under actual programmatic conditions in 3 urban slums in Pakistan. The vaccines used in this study are internationally produced and locally licensed. A complimentary, targeted, basic typhoid prevention health education program for the entire population at the initiation of the project will be provided and the actual Vi-demonstration project will be preceded by a 12-month typhoid surveillance activity.
Secondary objectives of this trial are:
A nested, prospective matched case-control study is included in the trial in order to study typhoid risk factors among children in Karachi.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Typhoid Vi polysaccharide vaccine |
|
| 2 | Active Comparator | Inactivated Hepatitis A vaccine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Typhoid Vi vaccine | Biological | Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total protection against S. typhi | 2 years from zero time |
| Measure | Description | Time Frame |
|---|---|---|
| Indirect protection against s. typhi | two years from zero time | |
| Overall protection against s. typhi | 2 years from zero time | |
| Adverse event(s) following immunization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zulfiqar A Bhutta, MBBS, PhD | Aga Khan University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aga Khan University | Karachi | Pakistan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15450121 | Background | Ali M, Rasool S, Park JK, Saeed S, Ochiai RL, Nizami Q, Acosta CJ, Bhutta Z. Use of satellite imagery in constructing a household GIS database for health studies in Karachi, Pakistan. Int J Health Geogr. 2004 Sep 28;3(1):20. doi: 10.1186/1476-072X-3-20. | |
| 15609776 | Background | Acosta CJ, Galindo CM, Ochiai RL, Danovaro-Holliday MC, Page AL, Thiem VD, Park JK, Park E, Koo H, Wang XY, Abu-Elyazeed R, Ali M, Albert MJ, Ivanoff B, Pang T, Xu ZY, Clemens JD. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia. J Health Popul Nutr. 2004 Sep;22(3):240-5. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014435 | Typhoid Fever |
| D010284 | Paratyphoid Fever |
| D012480 | Salmonella Infections |
| ID | Term |
|---|---|
| D004756 | Enterobacteriaceae Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
| ID | Term |
|---|---|
| C057664 | Vi polysaccharide vaccine, typhoid |
| D022362 | Hepatitis A Vaccines |
| ID | Term |
|---|---|
| D014761 | Viral Hepatitis Vaccines |
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
Not provided
Not provided
| INDUSTRY |
Not provided
Not provided
Not provided
Not provided
| Hepatitis A vaccine | Biological | single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen |
|
|
| 30 days from vaccination |
| D007239 | Infections |
| D045424 |
| Complex Mixtures |